A carregar...

Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer

BACKGROUND: Targeting BRAF V600E mutation has been proven effective in the treatment of several types of cancer. In endometrial adenocarcinoma, the BRAF V600E mutation has been rarely reported. Whether targeting BRAF oncogene may represent a plausible therapeutic strategy for the rare patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Exp Hematol Oncol
Main Authors: Moschetta, Michele, Mak, Gabriel, Hauser, Joana, Davies, Catriona, Uccello, Mario, Arkenau, Hendrik-Tobias
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5223353/
https://ncbi.nlm.nih.gov/pubmed/28078189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-016-0061-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!